Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
तुलना करने के लिए मीट्रिक्स | EVLO | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधEVLOपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 0.0x | −2.6x | −0.6x | |
PEG अनुपात | 0.00 | −0.12 | 0.00 | |
क़ीमत/बुक | 0.0x | 2.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 38.0x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 49,900.0% | 161.9% | 47.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | 13.0% | 7.1% | अनलॉक करें |